Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 5
1992 4
1993 2
1995 1
1996 3
1997 1
1998 1
1999 3
2000 7
2001 5
2003 1
2004 4
2005 4
2006 8
2007 10
2008 3
2009 2
2010 8
2011 8
2012 8
2013 2
2014 4
2015 8
2016 5
2017 3
2018 2
2019 5
2020 6
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Immune Design.
Ter Meulen J, Brady SR. Ter Meulen J, et al. Hum Vaccin Immunother. 2017 Jan 2;13(1):15-16. doi: 10.1080/21645515.2016.1239490. Epub 2016 Nov 21. Hum Vaccin Immunother. 2017. PMID: 27870594 Free PMC article. No abstract available.
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
Seo YD, Lu H, Black G, Smythe K, Yu Y, Hsu C, Ng J, Hermida de Viveiros P, Warren EH, Schroeder BA, O'Malley RB, Cranmer LD, Loggers ET, Wagner MJ, Bonham L, Pillarisetty VG, Kane G, Berglund P, Hsu FJ, Mi X, Alexiev BA, Pierce RH, Riddell SR, Jones RL, Ter Meulen J, Kim EY, Pollack SM. Seo YD, et al. Among authors: ter meulen j. JAMA Oncol. 2023 Dec 1;9(12):1660-1668. doi: 10.1001/jamaoncol.2023.4015. JAMA Oncol. 2023. PMID: 37824131 Free PMC article. Clinical Trial.
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D, Temperton N, Mayora-Neto M, Da Costa K, Cantoni D, Horlacher R, Günther A, Brosig A, Morath J, Jakobs B, Groettrup M, Hoschuetzky H, Rohayem J, Ter Meulen J. Horvath D, et al. Among authors: ter meulen j. Sci Rep. 2023 Mar 21;13(1):4648. doi: 10.1038/s41598-023-31198-3. Sci Rep. 2023. PMID: 36944687 Free PMC article.
117 results